Patents Assigned to Theracos, Inc.
  • Process for the preparation of benzylbenzene SGLT2 inhibitors
    Patent number: 9193751
    Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: November 24, 2015
    Assignee: Theracos, Inc.
    Inventors: Baihua Xu, Binhua Lv, Ge Xu, Brian Seed, Jacques Y. Roberge
  • Deuterated benzylbenzene derivatives and methods of use
    Patent number: 9061060
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: June 23, 2015
    Assignee: Theracos Inc.
    Inventors: Brian Seed, Binhua Lv, Jacques Y. Roberge, Yuanwei Chen, Kun Peng, Jiajia Dong, Baihua Xu, Jiyan Du, Lili Zhang, Xinxing Tang, Ge Xu, Yan Feng, Min Xu
  • Processes for the preparation of SGLT2 inhibitors
    Patent number: 9006403
    Abstract: Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 14, 2015
    Assignee: Theracos, Inc.
    Inventors: Jason Liou, Yuelin Wu, Shengbin Li, Ge Xu
  • Crystalline form of benzylbenzene SGLT2 inhibitor
    Patent number: 8987323
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 24, 2015
    Assignee: Theracos, Inc.
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Benzylbenzene derivatives and methods of use
    Patent number: 8802637
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 12, 2014
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Binhua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • Treating obesity with muscarinic receptor Mantagonists
    Patent number: 8748419
    Abstract: Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: June 10, 2014
    Assignee: Theracos, Inc.
    Inventors: Brian Seed, Jordan Mechanic
  • Treating psychological conditions using muscarinic receptor Mantagonists
    Patent number: 8735389
    Abstract: Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: May 27, 2014
    Assignee: Theracos, Inc.
    Inventors: Brian Seed, Jordan Mechanic
  • BENZYLBENZENE DERIVATIVES AND METHODS OF USE
    Publication number: 20140031300
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR
    Publication number: 20140011754
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: June 13, 2011
    Publication date: January 9, 2014
    Applicant: Theracos, Inc.
    Inventors: Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Benzylbenzene derivatives and methods of use
    Patent number: 8575321
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: November 5, 2013
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Roberge
  • PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS
    Publication number: 20130267694
    Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
    Type: Application
    Filed: May 8, 2013
    Publication date: October 10, 2013
    Applicant: Theracos, Inc.
    Inventors: Baihua Xu, Binhua Lv, Ge Xu, Brian Seed, Jacques Y. Roberge
  • Combination therapy for the treatment of diabetes
    Patent number: 8440655
    Abstract: The present invention provides methods of treating, reducing, preventing, or inhibiting symptoms of diabetes and/or lowering plasma levels of HbA1c by co-administration of therapeutic or subtherapeutic doses of telenzepine and sertraline to a subject in need thereof.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: May 14, 2013
    Assignee: Theracos, Inc.
    Inventors: Brian Seed, Jordan Mechanic
  • Processes for the Preparation of SGLT2 Inhibitors
    Publication number: 20130046088
    Abstract: Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.
    Type: Application
    Filed: August 31, 2012
    Publication date: February 21, 2013
    Applicant: Theracos, Inc.
    Inventors: Jason Liou, Yuelin Wu, Shengbin Li, Ge Xu
  • BENZYLBENZENE DERIVATIVES AND METHODS OF USE
    Publication number: 20120329732
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Application
    Filed: December 21, 2011
    Publication date: December 27, 2012
    Applicant: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • Processes for the preparation of SGLT2 inhibitors
    Patent number: 8283454
    Abstract: Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: October 9, 2012
    Assignee: Theracos, Inc.
    Inventors: Jason Liou, Yuelin Wu, Shengbin Li, Ge Xu
  • CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR
    Publication number: 20120238510
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: June 13, 2011
    Publication date: September 20, 2012
    Applicant: Theracos, Inc.
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Benzylphenyl cyclohexane derivatives and methods of use
    Patent number: 8129434
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: March 6, 2012
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Kun Peng, Lili Zhang, Binhua Lv, Baihua Xu, Jiajia Dong, Jiyan Du, Yan Feng, Ge Xu, Vasanthakumar Rajappan, Brian Seed
  • Benzylbenzene derivatives and methods of use
    Patent number: 8106021
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: January 31, 2012
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • COMBINATION THERAPY FOR THE TREATMENT OF DIABETES
    Publication number: 20110312946
    Abstract: The present invention provides methods of treating, reducing, preventing, or inhibiting symptoms of diabetes and/or lowering plasma levels of HbA1c by co-administration of therapeutic or subtherapeutic doses of telenzepine and sertraline to a subject in need thereof.
    Type: Application
    Filed: June 21, 2011
    Publication date: December 22, 2011
    Applicant: Theracos, Inc.
    Inventors: Brian Seed, Jordan Mechanic
  • BENZYLBENZENE DERIVATIVES AND METHODS OF USE
    Publication number: 20110207661
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Application
    Filed: November 1, 2010
    Publication date: August 25, 2011
    Applicant: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge